Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13102206 | 0.84 | BCHE (0.78) | BCHEKDM2B | |
| Bromide SCHEMBL10773365 | 0.83 | BCHE (0.86) | BCHE | |
| SCHEMBL12320825 | 0.83 | SLC6A1 (0.50) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL29312335 | 0.83 | HSD17B10 (0.46) | BCHEKDM4EALDH1A1HSD17B10CCR5 | |
| SCHEMBL7389564 | 0.83 | SLC6A1 (0.50) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL13995264 | 0.81 | BCHE (0.64) | BCHEKDM4EALDH1A1KDM2BSMN1; SMN2 | |
| SCHEMBL19815625 | 0.81 | BCHE (0.68) | BCHEKDM4EALDH1A1HTTKDM2B | |
| SCHEMBL21047445 | 0.81 | BCHE (0.64) | BCHEKDM4EALDH1A1HTTKDM2B | |
| SCHEMBL771548 | 0.80 | BCHE (0.62) | BCHEKDM4EALDH1A1HTTKDM2B | |
| SCHEMBL14505196 | 0.77 | BCHE (0.59) | BCHEKDM4EALDH1A1HTTKDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2022-04-19 | — | — | US | disclosed |
| US-20200385373-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-10 | — | — | US | disclosed |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-08-25 | — | — | US | disclosed |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | BCHE 4812/4885KDM4E 3969/4885ALDH1A1 434/4885 |
| US-20200385373-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | BCHE 4812/4885KDM4E 3969/4885ALDH1A1 434/4885 |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | BCHE 4766/4885KDM4E 4194/4885ALDH1A1 428/4885 |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | BCHE 4766/4885KDM4E 4194/4885ALDH1A1 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.